XVIVO PERFUSION AB NPV revenue for the last year amounted to 598.00 M SEK, the most of which — 384.36 M SEK — came from its highest performing source at the moment, Thoracic, the year earlier bringing 296.35 M SEK. The greatest contribution to the revenue figure was made by United States — last year it brought XVIVO PERFUSION AB NPV 308.10 M SEK, and the year before that — 224.87 M SEK.